萊美藥業(300006.SZ)：實控人邱宇擬將22.71%的股份表決權委託予中恆集團 後者對公司預計總投資不超13.5億元
格隆匯1月3日丨萊美藥業(300006.SZ)公佈，近日，公司實際控制人邱宇與中恆集團就《戰略合作框架協議》中約定的表決權委託事項進行了商議。2020年1月2日中恆集團第八屆董事會第三十次會議審議通過了《廣西梧州中恆集團股份有限公司關於接受邱宇先生表決權委託的議案》，公司實際控制人邱宇擬與中恆集團簽署《表決權委託協議》。
邱宇同意在委託期限內將其直接持有萊美藥業的全部股份(截至目前，邱宇直接持有的萊美藥業股份合計約1.8450億股)所對應的表決權(佔萊美藥業表決權比例為22.71%)獨家且不可撤銷地委託中恆集團行使，中恆集團同意接受該委託。
委託的標的股份包括截至表決權委託協議簽署日邱宇直接持有的萊美藥業的全部股份，及在表決權委託協議約定的委託期間內邱宇因萊美藥業送股、公積金轉增、拆分股份和配股等原因而增加的直接持有的股份。
在表決權委託協議約定的表決權委託期限內，若邱宇在表決權委託協議簽署後依據協議約定減持萊美藥業股份或因法院強制執行而被動減持其持有的萊美藥業股份，則減持後邱宇持有的剩餘股份的表決權仍委託中恆集團行使，若邱宇在減持前應提前告知中恆集團，中恆集團對前述邱宇轉讓的股票在同等條件下享有優先購買權。如中恆集團行使優先購買權的，中恆集團可直接或通過中恆集團控制的關聯方受讓邱宇先生轉讓的股票。
中恆集團承諾於此次表決權委託協議生效後18個月內，在萊美藥業股價不低於2.1元/股，不高於9元/股的前提下，通過多種方式(包括但不限於二級市場增持，協議轉讓、司法拍賣、參與定增)增加投資萊美藥業股票，投資金額10億元。該項投資承諾的履行，需經過中恆集團內部相關決策程序通過後，方可執行。
中恆集團於2019年12月30日披露的對外投資公告中，擬以不低於3000萬元、不超過3.5億元增持萊美藥業的股票，該公告中的3.5億投資金額不包含在此項承諾中。中恆集團對萊美藥業股票的預計總投資金額不超過13.5億元。
交易完成後，公司通過引入國資戰略投資方有利於公司經營穩定和持續增長，後續雙方通過產業協同合作、金融資源支持等方式，促進公司在生物醫藥產業領域內進一步做精做強。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
